secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0000950170-24-035908
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics reports 2023 net loss $104.7M; cash $201.4M to fund to end 2025
--------------------------------------------------------------------------------

- Cash, equivalents & marketable securities $201.4M as of Dec 31, 2023; expected to fund operations through end of 2025.
- Net loss for FY 2023 was $104.7M ($2.38 per share) vs $101.1M ($2.60 per share) in 2022.
- Revenue from Acadia collaboration fell to $8.8M from $12.4M YoY.
- R&D expenses $82.2M (2022: $77.8M); G&A $41.3M (2022: $38.9M), driven by STK-001 and STK-002 development.
- Q4 2023 net loss $27.0M ($0.60 per share) vs $25.7M ($0.65 per share) in Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000095017024035908/0000950170-24-035908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000095017024035908/stok-20240325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-035908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer